Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Astellas Employee Won’t Appeal China Espionage Sentence
A Japanese employee of Astellas Pharma who was sentenced to three years and six months in prison in China for espionage does not plan to appeal, sources familiar with the matter said on July 19. The Beijing No. 2 Intermediate…
To read the full story
Related Article
- Astellas Employee Did Not Appeal, Prison Sentence Finalized in China
July 29, 2025
- Astellas Employee Sentenced to 3.5 Years in China for Spying
July 17, 2025
- Verdict Due July 16 for Astellas Employee Detained in China
July 14, 2025
- Astellas Pharma Employee Indicted in China
August 23, 2024
- Japan Will Persistently Urge China to Release Detained Astellas Employee: Govt
April 12, 2024
- 1 Year on, China Mulling Potential Indictment of Detained Astellas Employee
March 22, 2024
- Japan Ambassador Meets Astellas Employee Detained in China
November 29, 2023
- China Formally Arrests Astellas Employee, Japan Urges Immediate Release
October 20, 2023
- China to Soon Decide Whether to Arrest Detained Japanese Astellas Employee
September 21, 2023
- Japan Industry Frets Fate of Astellas Worker Held in China for Espionage Allegation
March 28, 2023
REGULATORY
- Officer Replacement Orders a “Last Resort” under PMD Act: MHLW Official
September 18, 2026
- Japan Panel Sees No Scientific Objection to Capvaxive NIP Addition
September 18, 2026
- Tavneos Blue Letter Action “Too Slow,” MHLW Panel Member Says
September 18, 2026
- Takaichi Tasks Ueno with Charting Growth Strategy for Drug Innovation
September 18, 2026
- Japan HIV, AIDS Cases Rise in H1 after 2025 Lows
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…